Related Experiment Video

Updated: Jun 24, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

FTY720 Inhibits Tumor Necrosis Factor-alpha-Induced Proliferation and Extracellular Signal-Regulated Kinase

T Böhler1, N Kamar, L Etienne

  • 1INSERM U858/I2MR EQ 10 Artériosclérose et Artériosclérose de Greffe, CHU Rangueil, Toulouse, France.

Transplantation Proceedings
|March 31, 2009
PubMed

Insights

The sphingolipid FTY720 inhibits tumor necrosis factor-alpha (TNF-alpha)-induced smooth muscle cell proliferation and signaling. This suggests FTY720 could be a potential therapeutic for chronic vascular rejection.

Area of Science:

  • Vascular Biology
  • Immunology
  • Pharmacology

Background:

  • Smooth muscle cells (SMC) play a critical role in vascular health and disease.
  • Tumor necrosis factor-alpha (TNF-alpha) is implicated in inflammatory processes contributing to vascular complications.
  • Chronic vascular rejection is a significant challenge in organ transplantation.

Purpose of the Study:

  • To investigate the effects of the sphingolipid FTY720 on TNF-alpha-induced proliferation and signal transduction in human SMC.
  • To determine if FTY720 can modulate key signaling pathways involved in SMC responses to TNF-alpha.

Main Methods:

  • Human SMC were treated with FTY720 and TNF-alpha.
  • Cell proliferation was assessed.
  • Extracellular signal-regulated kinase (ERK) phosphorylation, a key signaling event, was measured.

Main Results:

  • Clinically relevant concentrations of FTY720 significantly inhibited TNF-alpha-induced SMC proliferation.
  • FTY720 also suppressed TNF-alpha-induced ERK phosphorylation in SMC.
  • These findings indicate FTY720 modulates critical signaling pathways.

Conclusions:

  • FTY720 demonstrates potent inhibitory effects on TNF-alpha-mediated SMC proliferation and signaling.
  • These results suggest FTY720 holds promise as a therapeutic agent for preventing or treating chronic vascular rejection.
  • Further investigation into FTY720's role in vascular health is warranted.

More Related Videos

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...